Clinical Report: Evaluating the Effectiveness of Rituximab in Children with Nephrotic Syndrome

Overview

This study evaluates the efficacy of rituximab in pediatric patients with steroid-dependent or frequently relapsing nephrotic syndrome due to minimal change disease or focal segmental glomerulosclerosis. Results indicate that rituximab is effective in achieving remission and reducing relapse rates, with no significant differences between the two histological subtypes.

Background

Nephrotic syndrome is a common glomerular condition in children, often leading to steroid dependence or frequent relapses. Current treatments, including corticosteroids and immunosuppressants, have significant side effects, highlighting the need for effective alternatives. Rituximab, a monoclonal antibody, has shown promise in reducing relapses in this patient population.

Data Highlights

Key Findings

• All patients achieved clinical remission, with 90.5% attaining complete remission.
• Relapse rates decreased from a median of 2 to 0 within 1 year after rituximab treatment.
• No significant difference in relapse rates was found between patients receiving 1-2 doses versus 3-4 doses.
• Higher relapse-free survival was observed in the FSGS group compared to MCD controls.
• Rituximab was well tolerated among all patients.

Clinical Implications

Rituximab is an effective treatment option for children with steroid-dependent or frequently relapsing nephrotic syndrome, regardless of the underlying histological subtype. Clinicians should consider rituximab as a viable alternative to traditional immunosuppressants, particularly in patients with significant steroid-related side effects.

Conclusion

The findings support the use of rituximab in pediatric nephrotic syndrome, emphasizing its role in achieving remission and reducing relapse rates. Further studies are needed to validate these results in larger cohorts.

References

1. KDIGO, KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children, 2025 -- Guidelines on nephrotic syndrome management
2. PubMed, Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial, 2025 -- Study on rituximab efficacy
3. Bone Marrow Transplantation — Efficacy of Ruxolitinib in Managing Acute and Chronic Graft-Versus-Host Disease in Pediatric Patients: A Systematic Review and Meta-Analysis of Individual Patient Data
4. Clinical Rheumatology — Management of refractory juvenile dermatomyositis using tacrolimus
5. Clinical Rheumatology — Rituximab in the Treatment of Mixed Cryoglobulinemia: Insights and Consensus Recommendations from the Italian Cryoglobulinemia Study Group (GISC)
6. The ASCO Post — Update on Newer Treatments in Non-Hodgkin Lymphomas
7. KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children
8. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial - PubMed
9. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis - PubMed